Table 4.

Other AEs grouped into major organ systems in patients treated with PD-1/PDL-1 inhibitors

	TB death events (n=13)	TB alive events (n=59)	TB total (n=72)	AMI death events (n=1)	AMI alive events (n=12)	AMI total (n=13)
Pulmonary	5 (38.46%)	9 (15.25%)	14 (19.44%)	0	5 (41.66%)	5 (38.46%)
Infectious	3 (23.07%)	7 (11.86%)	10 (13.88%)	1 (100%)	0	1 (7.69%)
Endocrine	0	5 (8.47%)	5 (6.94%)	0	2 (16.66%)	2 (15.38%)
Gastrointestinal	2 (15.38%)	3 (5.08%)	5 (6.94%)	0	1 (8.33%)	1 (7.69%)
Hepatobiliary	1 (7.69%)	4 (6.77%)	5 (6.94%)	0	0	0
Cardiac	0	4 (6.77%)	4 (5.55%)	0	0	0
Haematological	0	3 (5.08%)	3 (4.16%)	0	0	0
Dermatological	0	3 (5.08%)	3 (4.16%)	0	2 (16.66%)	2 (15.38%)
Neurological	0	3 (5.08%)	3 (4.16%)	0	0	0
Vascular	1 (7.69%)	1 (1.69%)	2 (2.77%)	0	0	0
Infusion related	1 (7.69%)	0	1 (1.38%)	0	0	0
Rheumatological	0	1 (1.69%)	1 (1.38%)	0	0	0
Others	1 (7.69%)	4 (6.77%)	5 (6.94%)	1 (100%)	1 (8.33%)	2 (15.38%)

AEs, adverse events; AMI, atypical mycobacterial infection; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; TB, tuberculosis.